{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=26",
    "query": {
      "condition": "Neuroectodermal Tumors",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 5016,
    "total_pages": 502,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T10:28:42.523Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00067067",
      "title": "Investigating Endothelial Precursor Cells (EPCs)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Central Nervous System"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 84,
      "start_date": "2003-08",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00067067"
    },
    {
      "nct_id": "NCT01345136",
      "title": "Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 2",
        "Neuroma, Acoustic"
      ],
      "interventions": [
        {
          "name": "RAD001, everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2015-07-01",
      "completion_date": "2024-02-06",
      "has_results": false,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345136"
    },
    {
      "nct_id": "NCT03119064",
      "title": "BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Nanoliposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-11-30",
      "completion_date": "2021-10-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119064"
    },
    {
      "nct_id": "NCT00187109",
      "title": "Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Tumors",
        "Hepatic Cancer",
        "Neuroblastoma",
        "Osteosarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Thrombopoietin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2000-06",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2008-04-10",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00187109"
    },
    {
      "nct_id": "NCT03093909",
      "title": "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm of Bone and Articular Cartilage",
        "Malignant Neoplasms of Female Genital Organs",
        "Malignant Neoplasms of Independent (Primary) Multiple Sites",
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Malignant Neoplasm of Male Genital Organs",
        "Malignant Neoplasms of Mesothelial and Soft Tissue",
        "Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma",
        "Malignant Neoplasms of Thyroid and Other Endocrine Glands",
        "Malignant Neoplasms of Urinary Tract",
        "Melanoma and Other Malignant Neoplasms of Skin"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2017-11-22",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093909"
    },
    {
      "nct_id": "NCT00571116",
      "title": "Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Disulfiram",
          "type": "DRUG"
        },
        {
          "name": "Arsenic trioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571116"
    },
    {
      "nct_id": "NCT00589784",
      "title": "Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CNS Cancer",
        "Meningioma",
        "Intracranial Hemangiopericytoma",
        "Hemangioblastoma",
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589784"
    },
    {
      "nct_id": "NCT00031733",
      "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "alum adjuvant",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2002-02",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031733"
    },
    {
      "nct_id": "NCT02014116",
      "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Neoplasm Metastasis",
        "Melanoma",
        "Carcinoma, Non-Small-Cell Lung",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "LY3009120 capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2013-11-26",
      "completion_date": "2018-10-05",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014116"
    },
    {
      "nct_id": "NCT07259304",
      "title": "Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Central Nervous System Neoplasm",
        "Clinical Stage I Cutaneous Melanoma AJCC v8",
        "Clinical Stage IA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IB Cutaneous Melanoma AJCC v8",
        "Clinical Stage II Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Hodgkin Lymphoma",
        "Malignant Bone Neoplasm",
        "Malignant Brain Neoplasm",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Neoplasm",
        "Non-Hodgkin Lymphoma",
        "Pathologic Stage I Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage II Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Stage I Cervical Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage I Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage I Ovarian Cancer AJCC v8",
        "Stage I Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage I Uterine Corpus Cancer AJCC v8",
        "Stage IA Cervical Cancer AJCC v8",
        "Stage IA Ovarian Cancer AJCC v8",
        "Stage IA Uterine Corpus Cancer AJCC v8",
        "Stage IA1 Cervical Cancer AJCC v8",
        "Stage IA2 Cervical Cancer AJCC v8",
        "Stage IB Cervical Cancer AJCC v8",
        "Stage IB Ovarian Cancer AJCC v8",
        "Stage IB Uterine Corpus Cancer AJCC v8",
        "Stage IB1 Cervical Cancer AJCC v8",
        "Stage IB2 Cervical Cancer AJCC v8",
        "Stage IC Ovarian Cancer AJCC v8",
        "Stage II Cervical Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage II Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage II Ovarian Cancer AJCC v8",
        "Stage II Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage II Uterine Corpus Cancer AJCC v8",
        "Stage IIA Cervical Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIA Ovarian Cancer AJCC v8",
        "Stage IIA1 Cervical Cancer AJCC v8",
        "Stage IIA2 Cervical Cancer AJCC v8",
        "Stage IIB Cervical Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIB Ovarian Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 173,
      "start_date": "2021-11-24",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-30T10:28:42.523Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07259304"
    }
  ]
}